X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

Abbott Is Named Global Industry Leader in Sustainability for the Sixth Consecutive Year on the Dow Jones Sustainability Index (DJSI)

Content Team by Content Team
13th September 2018
in Americas, News
Abbott Is Named Global Industry Leader in Sustainability for the Sixth Consecutive Year on the Dow Jones Sustainability Index (DJSI)

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

For the sixth consecutive year, Abbott has been named the leading company in its industry by the Dow Jones Sustainability Index (DJSI), one of the most prestigious global benchmarks for corporate sustainability and responsibility. As the industry leader in Health Care Equipment & Supplies, Abbott is one of the 60 companies recognized for leading their respective global industries.

The DJSI designation recognizes companies for responsible and sustainable business, including economic, social and environmental performance. This is the 14th consecutive year that Abbott has been recognized for sustainability through its inclusion on the DJSI, including both the Dow Jones Sustainability World Index and North America Index.

“As a healthcare company, we recognize that the success of our business depends upon a range of factors — economic, social and environmental. Our work is aligned with the United Nations Sustainable Development Goals to ensure our efforts are focused on the needs deemed most important to global well-being,” said Miles D. White, chairman and chief executive officer, Abbott. “This year marks Abbott’s 130th anniversary. That long history of success gives us a particular appreciation for sustainability, and what it takes to achieve it. We will continue to bring that perspective and that commitment to our efforts to be a productive and responsible corporate citizen.”

Abbott earned the highest industry scores in economic and social performance. The company’s score of 82 was more than double the average score of 33 for other companies in the industry.

Abbott also achieved the top industry scores in nine of DJSI’s 24 specific economic, social and environmental criteria, including corporate governance; talent attraction and retention; marketing practices; customer relationship management; health outcome contribution; tax strategy; environmental reporting and social reporting; and corporate citizenship and philanthropy.

In addition to being included in the Dow Jones Sustainability Index for 14 years, Abbott was recently named to the Fortune magazine “Change the World” list for creating positive social impact through business. The company also was named one of the 100 Best Corporate Citizens by Corporate Responsibility magazine for 10 consecutive years, and was named the 2018 Corporate Citizen of the Year by the Executives’ Club of Chicago. To learn more about Abbott’s sustainability initiatives and reporting, please visit www.abbott.com/sustainability.

ABOUT S&P DOW JONES INDICES
The Dow Jones Sustainability Indices (DJSI) are maintained collaboratively by S&P Dow Jones Indices (S&P DJI), one of the world’s leading index providers, and RobecoSAM, the investment specialist that has focused exclusively on Sustainability Investing (SI) for over 23 years. Launched in 1999, the DJSI World represents the gold standard for corporate sustainability and is the first global index to track the leading sustainability-driven companies based on RobecoSAM’s analysis of financially material Environmental, Social, and Governance (ESG) factors and S&P DJI’s robust index methodology. RobecoSAM assesses the world’s largest companies via its annual Corporate Sustainability Assessment (CSA), which uses a consistent, rules-based methodology to convert an average of 600 data points per company into one overall score. This score determines inclusion in the DJSI.

For additional information on the DJSI and the changes to its components’ numbers, please visit: RobecoSAM’s DJSI review page and S&P Dow Jones Indices.

ABOUT ABBOTT
At Abbott, we’re committed to helping people live their best possible life through the power of health. For more than 125 years, we’ve brought new products and technologies to the world – in nutrition, diagnostics, medical devices and branded generic pharmaceuticals – that create more possibilities for more people at all stages of life. Today, 99,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve. Connect with us at www.abbott.com,

Previous Post

New Lilly Diabetes Center of Excellence Established at the Indiana Bioscience Research Institute

Next Post

Thailand LAB INTERNATIONAL 2018 ends with 9,109 trade visitors from 43 countries, and is ready to become a Top 3 Laboratory Exhibition in South East Asia!

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post

Thailand LAB INTERNATIONAL 2018 ends with 9,109 trade visitors from 43 countries, and is ready to become a Top 3 Laboratory Exhibition in South East Asia!

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In